FN1 and cancer: Thus, the third key feature of our design is that Dox‐Fn is transported within pH‐responsible and IL15c‐presenting nanovesicles, which have shown tumor‐targeting capability.[16, 28] The Dox‐Fn is designed to be released in the tumor microenvironment with the help of pH‐M70 to facilitate its tumor penetration and TfR1‐mediated endocytosis by cancer cells.